Parthenogenetic activation of domestic cat oocytes using ethanol, calcium ionophore, cycloheximide and a magnetic field.
The objective of this study was to evaluate parthenogenetic activation of domestic cat oocytes after being exposed to either ethanol, magnetic field, calcium ionophore A23187, or cycloheximide and a combination of these agents. We also wished to evaluate the usefulness of the magnetic field for oocyte activation. In vitro matured oocytes subjected to artificial activation were randomly assigned into eight groups according to activating agents: (1) 10% ethanol; (2) the magnetic field (slow-changing, homogenous magnetic field with low values of induction); (3) 10% ethanol plus magnetic field; (4) 10 microM calcium ionophore A23187; (5) 10 microM calcium ionophore A23187 plus magnetic field; (6) 10% ethanol and 10 microg/mL of cycloheximide; (7) 10% ethanol and 10 microg/mL of cycloheximide plus magnetic field; (8) oocytes were not exposed to any of the activating agents. After activation oocytes were stained with Hoechst 33258 and parthenogenetic activation was defined as oocytes containing pronuclei and second polar bodies or two to four or six nuclei (embryonic cleavage). The total activation rate by using different activation treatments was 40%. The addition of the magnetic field to ethanol or calcium ionophore treatments resulted in increased parthenogenetic activation rates from 47% to 75%, and from 19% to 48%, respectively (P<0.001). Instead, when the magnetic field was added to ethanol and cycloheximide treatment, activation rate decreased from 48% to 30%. Oocytes activated with magnetic field only gave the lowest activation rate (12%). We concluded that a magnetic field can be used as an activating agent, and the combination of ethanol and magnetic field is an effective method for domestic cat oocyte activation.
Grabiec
A
A
Department of Clinical Science, Faculty of Veterinary Medicine, Warsaw Agricultural University, Nowoursynowska 159c, 02-776 Warszawa, Poland.
Max
A
A
Tischner
M
M
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology*; D002415:Cats / Q000502:physiology*; D003513:Cycloheximide / Q000494:pharmacology*; D000431:Ethanol / Q000494:pharmacology*; D005260:Female; D007476:Ionophores / Q000494:pharmacology; D008280:Magnetics; D009865:Oocytes / Q000187:drug effects*; D010312:Parthenogenesis / Q000187:drug effects*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012997:Solvents / Q000494:pharmacology
D007476:Ionophores; D011500:Protein Synthesis Inhibitors; D012997:Solvents; D000001:Calcimycin; D000431:Ethanol; D003513:Cycloheximide